Travere Therapeutics (TVTX) AI Stock Analysis

636 Followers

Travere Therapeutics

(NASDAQ:TVTX)

Select Model

Rating:51Neutral

Price Target:$50.00▲(1.19% Upside)

Action:reiterated

Date:11/04/26

The score is held back primarily by financial risk: worsening TTM losses versus 2025 and a pressured balance sheet with higher debt and minimal equity, despite strong gross margins and improved TTM cash generation. Technicals are also weak with the stock trading below key moving averages and negative MACD. Offsetting these, the latest earnings call was notably constructive on commercial traction and long-term outlook, supporting a mid-range score rather than a low one.

Positive Factors

Revenue Scale and Gross MarginRapid revenue expansion and consistently exceptional gross margins indicate strong product economics and growing commercial reach. This combination can support reinvestment in the pipeline and commercialization while providing a durable foundation for improving operating leverage over the next several quarters.

Negative Factors

High Leverage and Thin EquitySharp debt growth alongside substantial equity erosion leaves Travere with a very thin capital cushion and elevated leverage. This reduces financial flexibility if operating performance weakens and can constrain the company's ability to fund growth, absorb volatility, or allocate capital without balance-sheet pressure.

Travere Therapeutics (TVTX) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $4.66B
Dividend Yield: ―
Average Volume (3M): 1.89M
Price to Earnings (P/E): -31.7
Beta (1Y): 1.79
Revenue Growth: 49.38%
EPS Growth: -58.47%
Country: US
Employees: 497
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Travere Therapeutics Business Overview & Revenue Model

Company Description

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease...

How the Company Makes Money

Travere Therapeutics makes money primarily through net product sales of FILSPARI (sparsentan) in the United States. Revenue is generated by selling FILSPARI into the U.S. specialty pharmaceutical channel (e.g., specialty pharmacies/wholesalers) for d...

Travere Therapeutics Earnings Call Summary

Earnings Call Date:Nov 01, 2026(Q3-2026)|% Change Since:0.30%|Next Earnings Date:Feb 24, 2027

Earnings Call SentimentPositive

The call was strongly positive, characterized by record FILSPARI sales, approximately 120% year-over-year product growth, strong demand and persistence across IgA nephropathy and FSGS, encouraging clinical data, and continued pipeline and patent progress. The main challenges were expected fourth-quarter inventory normalization, a slight sequential decline in IgA nephropathy demand, anticipated gross-to-net pressure, substantial licensing-related expense, and the upcoming CEO transition. Positive operating momentum and pipeline progress significantly outweighed the stated headwinds.

Positive Updates

FILSPARI Quarterly Sales Surpassed $200 Million

Third-quarter FILSPARI U.S. net product sales reached $200.2 million, representing approximately 120% year-over-year growth. Total U.S. net product sales were $220.2 million, and total revenue was $224.6 million.

Negative Updates

Fourth-Quarter Sales Headwind From Specialty Pharmacy Inventory

Orders from specialty pharmacy partners increased inventory above historical levels and contributed approximately $8 million to third-quarter FILSPARI net sales. The company expects fourth-quarter net sales to be reduced by approximately the same amount as specialty pharmacies dispense existing stock to return to normal inventory levels.

Company Guidance

Management reiterated confidence in achieving or exceeding more than $3 billion in annual FILSPARI sales by 2033, with strong demand in both indications and expectations for an accelerated adoption curve and then a sustained demand moving forward; fourth quarter FILSPARI net sales are expected to be reduced by approximately $8 million, while full year gross to net discounts for FILSPARI are expected to be in the mid-20 percent range. Management expects top line results from the phase 3 HARMONY study in the second half of 2027, is on track to initiate SPARSLITE later this year and anticipates sharing data in 2027, plans to submit a U.S. IND for Civorebrutinib by year-end, and said the U.S. IND is planned for this quarter; no guidance was provided on patient start forms.

Travere Therapeutics Financial Statement Overview

Summary

Rapid revenue scaling and consistently very high gross margins are major positives, and TTM operating/free cash flow turned strongly positive. However, TTM profitability deteriorated versus 2025 (EBITDA swung negative and net losses widened) and the balance sheet adds risk with sharply higher debt and a very thin equity cushion.

Income Statement

46Neutral

Balance Sheet

28Negative

Cash Flow

70Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	651.03M	490.73M	233.18M	145.24M	109.46M	131.84M
Gross Profit	616.67M	480.39M	225.43M	133.79M	105.04M	128.02M
EBITDA	-98.07M	22.22M	-265.77M	-326.25M	-299.42M	-184.46M
Net Income	-121.51M	-25.55M	-321.55M	-111.40M	-278.48M	-180.09M
Balance Sheet
Total Assets	848.23M	605.19M	594.13M	788.91M	672.59M	776.63M
Cash, Cash Equivalents and Short-Term Investments	471.82M	322.80M	370.70M	566.85M	450.25M	552.88M
Total Debt	616.15M	328.73M	401.58M	404.78M	407.49M	261.99M
Total Liabilities	825.64M	490.36M	535.05M	588.10M	629.73M	474.52M
Stockholders Equity	22.58M	114.83M	59.08M	200.81M	42.85M	302.11M
Cash Flow
Free Cash Flow	135.54M	37.78M	-338.69M	-321.61M	-214.66M	-38.94M
Operating Cash Flow	176.59M	37.78M	-237.47M	-280.02M	-186.29M	-14.79M
Investing Cash Flow	-409.20M	27.89M	99.33M	55.78M	-32.55M	-137.62M
Financing Cash Flow	245.69M	-33.47M	139.42M	218.75M	117.57M	231.68M

Travere Therapeutics Technical Analysis

Technical Analysis SentimentNegative

Last Price49.41

Price Trends

50DMA58.42Negative

100DMA58.32Negative

200DMA46.83Positive

Market Momentum

MACD-2.25Negative

RSI33.17Neutral

STOCH28.79Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVTX, the sentiment is Negative. The current price of 49.41 is below the 20-day moving average (MA) of 51.31, below the 50-day MA of 58.42, and above the 200-day MA of 46.83, indicating a neutral trend. The MACD of -2.25 indicates Negative momentum. The RSI at 33.17 is Neutral, neither overbought nor oversold. The STOCH value of 28.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TVTX.

Travere Therapeutics Risk Analysis

Travere Therapeutics disclosed 61 risk factors in its most recent earnings report. Travere Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.Our ability to realize the anticipated benefits of in-licensed products and collaboration arrangements depends on several factors, many of which are outside of our control.*Q2, 2026

2.If we fail to establish or maintain successful collaborations or licensing arrangements, including cross-border collaborations, our business could be adversely affected.*Q2, 2026

Travere Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TVTX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	84Outperform	$2.16B	6.99	51.92%	―	21.04%	312.89%
IMVT	53Neutral	$5.87B	-10.30	-69.59%	―	―	1.28%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VERA	51Neutral	$2.18B	-5.24	-84.13%	―	―	-63.94%
TVTX	51Neutral	$4.64B	-31.67	-186.46%	―	49.38%	-58.47%
IONS	48Neutral	$6.85B	-11.68	-110.84%	―	-7.49%	-98.12%
OMER	48Neutral	$1.29B	9.56	-109.40%	―	―	―

* Healthcare Sector Average

Performance Comparison

TVTX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TVTX	Travere Therapeutics, Inc.	49.41	15.69	46.53%
IONS	Ionis Pharmaceuticals Inc.	40.42	-34.26	-45.88%
OMER	Omeros Corporation	18.27	11.28	161.37%
AUPH	Aurinia Pharmaceuticals	16.56	2.11	14.60%
IMVT	Immunovant, Inc.	29.04	5.44	23.05%
VERA	Vera Therapeutics, Inc.	30.71	6.61	27.43%

Travere Therapeutics Corporate Events

Executive/Board Changes

Travere Therapeutics appoints new CEO Bradley Campbell

Neutral

Sep 21, 2026

On September 21, 2026, Travere Therapeutics announced that President and Chief Executive Officer Eric Dube, Ph.D., will step down from his roles, including his board seat, effective December 1, 2026, under a detailed Transition and Separation Agreeme...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026

Travere Therapeutics AI Stock Analysis